摘要
目的研究喹硫平与利培酮治疗精神分裂症的疗效及安全性。方法按随机数字表法将2013年在本院精神病科住院的精神分裂症患者随机分为喹硫平组和利培酮组,每组各40例。喹硫平组给予喹硫平(496±65)mg/d治疗,利培酮组给予利培酮(3.1±0.3)mg/d治疗。疗程8周,从PANSS减分率评价其疗效,同时以不良反应症状量表(TESS)评定副反应。结果喹硫平组总有效率为72.5%,利培酮组总有效率为75.0%,两组疗效差异无统计学意义(P>0.05)。喹硫平组体位性低血压发生率明显高于利培酮组,利培酮组体重增加及锥体外系反应发生率显著高于喹硫平组,组间比较差异有统计学意义(P<0.05)。结论喹硫平与利培酮治疗精神分裂症疗效相当,安全性良好。
Objective To observe efficacy and safety of quetiapine and risperidone to patients with schizophrenia. Methods Participants included 80 patients with schizophrenia,accepted quetiapine（ 496 ± 65）mg / d and risperidone（ 3. 1 ± 0. 3） mg / d respectively for eight weeks,and curative effect and safety were observed. Results The total efficiency rate of quetiapine group and risperidone group was 72. 5% and 75%respectively,the effects of quetiapine and risperidone in schizophrenic patients had no significantly difference（ p 〉0. 05）. The incidence of postural hypotension in quetiapine group was higher than that in risperidone group,but the incidence of extrapyramidal side effects and weight gain in quetiapine group was lower than that in risperidone group,there was significantly difference（ P〈0. 05）. Conclusions Quetiapine and risperidone have similar efficiency in the treatment of schizophrenic patients,and are safe and generally well-tolerated.
出处
《齐齐哈尔医学院学报》
2015年第28期4252-4254,共3页
Journal of Qiqihar Medical University
